Takeda Pharmaceutical, Santhera Pharmaceuticals to Collaborate to Develop and Commercialize Idebenone, Drug Candidate for Friedreich's Ataxia.Tokyo, Japan, Aug 4, 2005 - (JCNN JCNN Japan Corporate News Network ) - Takeda Pharmaceutical and Santhera Pharmaceuticals jointly announced on August 3 that the two companies have signed an agreement for Idebenone, (SNT-MC17), a drug candidate for Friedreich's Ataxia Friedreich's Ataxia Definition Friedreich's ataxia (FA) is an inherited, progressive nervous system disorder causing loss of balance and coordination. Description Ataxia is a condition marked by impaired coordination. developed by Takeda. Under the terms of the agreement, Takeda will provide data collected from its nonclinical studies Nonclinical or Pre-Clinical studies are research studies that are conducted, typically on animals, before a permit for a clinical trial on humans can be obtained. Pre-clinical studies serve a vital role in the drug discovery and development processes. in the US and Santhera will proceed with development and apply for approval of the agent in Europe and the US. In addition, Takeda will pay its partner an upfront payment of 5 million euros as well as development milestones and royalties. Phase III clinical trails will soon start in Europe and the US. Upon commercialization of the agent, Takeda will market it in Europe while Santhera will handle sales in the US and supply the product. Friedreich's Ataxia, a spinocerebellar degeneration spinocerebellar degeneration Friedreich's ataxia, see there , is an inherited disease that causes progressive damage to the nervous system, resulting in muscle weakness, speech problems and heart disease. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion